Miniatura

Fitxers

1-s2.0-S2213177921005837-main.pdf (505.16 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-03-01

Llicència de publicació

cc by (c) Solomon, Scott D. et al., 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/185580

Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.jchf.2021.11.006

Resum

OBJECTIVES This report describes the baseline clinical profiles and management of DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure) trial participants and how these compare with those in other contemporary heart failure with preserved ejection fraction trials.BACKGROUND The DELIVER trial was designed to evaluate the effects of the sodium-glucose cotransporter-2 inhibitor dapagliflozin on cardiovascular death, heart failure (HF) hospitalization, or urgent HF visits in patients with HF with mildly reduced and preserved left ventricular ejection fraction (LVEF).METHODS Adults with symptomatic HF and LVEF > 40%, with or without type 2 diabetes mellitus, elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and evidence of structural heart disease were randomized to dapagliflozin 10 mg once daily or matching placebo.RESULTS A total of 6,263 patients were randomized (mean age: 72 & PLUSMN; 10 years; 44% women; 45% type 2 diabetes mellitus; 45% with body mass index $30 kg/m(2); and 57% with history of atrial fibrillation or flutter). Most participants had New York Heart Association functional class II symptoms (75%). Baseline mean LVEF was 54.2 & PLUSMN; 8.8% and median NT-proBNP of 1,399 pg/mL (IQR: 962 to 2,210 pg/mL) for patients in atrial fibrillation/flutter compared with 716 pg/mL (IQR: 469 to 1,281 pg/mL) in those who were not. Patients in both hospitalized and ambulatory settings were enrolled, including 10% enrolled in-hospital or within 30 days of a hospitalization for HF. Eighteen percent of participants had HF with improved LVEF. CONCLUSIONS DELIVER is the largest and broadest clinical trial of this population to date and enrolled high-risk, welltreated patients with HF with mildly reduced and preserved LVEF. (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure [NCT03619213]).

Matèries

Diabetis, Assaigs clínics, Heart failure, Envelliment

Matèries (anglès)

Diabetes, Clinical trials, Insuficiència cardíaca, Aging

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

SOLOMON, Scott d., VADUGANATHAN, Muthiah, CLAGGETT, Brian l., DE BOER, Rudolf a., DEMETS, David, HERNÁNDEZ, Adrian f., INZUCCHI, Silvio e., KOSIBOROD, Mikhail n., LAM, Carolyn s.p., MARTÍNEZ, Felipe, SHAH, Sanjiv j., BELOHLAVEK, Jan, CHIANG, Chern-en, WILLEM BORLEFFS, C. jan, COMÍN COLET, Josep, DOBREANU, Dan, DROZDZ, Jaroslaw, FANG, James c., ALCOCER GAMBA, Marco antonio, AL HABEEB, Waleed, HAN, Yaling, CABRERA HONORIO, Jose walter, JANSSENS, Stefan p., KATOVA, Tsvetana, KITAKAZE, Masafumi, MERKELY, Bela, O’MEARA, Eileen, KERR SARAIVA, Jose francisco, TERESCHENKO, Sergey n., THIERER, Jorge, VARDENY, Orly, VERMA, Subodh, VINH, Pham nguyen, WILDERÄNG, Ulrica, ZAOZERSKA, Natalia, LINDHOLM, Daniel, PETERSSON, Magnus, MCMURRAY, John j.v.. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction. _JACC: Heart Failure_. 2022. Vol. 10, núm. 3, pàgs. 184-197. [consulta: 22 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/185580]

Exportar metadades

JSON - METS

Compartir registre